551 related articles for article (PubMed ID: 12374669)
21. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
de Jong FA; Verweij J
Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
[TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.
Sawaki A; Yamao K
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S44-9. PubMed ID: 15309514
[TBL] [Abstract][Full Text] [Related]
23. F-18 FDG PET imaging in gastrointestinal stromal tumor.
Reddy MP; Reddy P; Lilien DL
Clin Nucl Med; 2003 Aug; 28(8):677-9. PubMed ID: 12897659
[TBL] [Abstract][Full Text] [Related]
24. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
25. Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: case report and literature review.
Saad Aldin E; Mourad F; Tfayli A
Jpn J Clin Oncol; 2012 May; 42(5):447-50. PubMed ID: 22422898
[TBL] [Abstract][Full Text] [Related]
26. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
[TBL] [Abstract][Full Text] [Related]
27. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?
Scaife CL; Hunt KK; Patel SR; Benjamin RS; Burgess MA; Chen LL; Trent J; Raymond AK; Cormier JN; Pisters PW; Pollock RE; Feig BW
Am J Surg; 2003 Dec; 186(6):665-9. PubMed ID: 14672776
[TBL] [Abstract][Full Text] [Related]
28. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
van Oosterom AT; Judson I; Verweij J; Stroobants S; Donato di Paola E; Dimitrijevic S; Martens M; Webb A; Sciot R; Van Glabbeke M; Silberman S; Nielsen OS;
Lancet; 2001 Oct; 358(9291):1421-3. PubMed ID: 11705489
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
31. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
33. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST).
Gulati AP; Saif MW
Anticancer Res; 2012 Apr; 32(4):1375-7. PubMed ID: 22493373
[TBL] [Abstract][Full Text] [Related]
34. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
Wu PC; Langerman A; Ryan CW; Hart J; Swiger S; Posner MC
Surgery; 2003 Oct; 134(4):656-65; discussion 665-6. PubMed ID: 14605627
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
[TBL] [Abstract][Full Text] [Related]
36. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
Koh JS; Trent J; Chen L; El-Naggar A; Hunt K; Pollock R; Zhang W
Histol Histopathol; 2004 Apr; 19(2):565-74. PubMed ID: 15024716
[TBL] [Abstract][Full Text] [Related]
37. [Imatinib--a breakthrough in the treatment of gastrointestinal stromal tumors (GIST)].
Larsen JB
Ugeskr Laeger; 2003 Sep; 165(37):3503-7. PubMed ID: 14531349
[TBL] [Abstract][Full Text] [Related]
38. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
39. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
[TBL] [Abstract][Full Text] [Related]
40. [Effect of imatinib treatment of gastrointestinal stromal tumors].
Eckhardt S; Pápai Z; Bodoky G; Horti J; Tamás K; Nagy T; Orosz Z; Sápi Z; Gödény M; Jakab K; Esik O; Trón L; Besznyák I
Orv Hetil; 2003 Nov; 144(45):2207-12. PubMed ID: 14686005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
